294 related articles for article (PubMed ID: 37453616)
41. Testosterone/estradiol ratio regulates NO-induced bladder relaxation and responsiveness to PDE5 inhibitors.
Vignozzi L; Filippi S; Morelli A; Comeglio P; Cellai I; Sarchielli E; Maneschi E; Mancina R; Gacci M; Vannelli GB; Maggi M
J Sex Med; 2012 Dec; 9(12):3028-40. PubMed ID: 23057807
[TBL] [Abstract][Full Text] [Related]
42. Preservation of nitric oxide-induced relaxation of porcine coronary artery: roles of the dimers of soluble guanylyl cyclase, phosphodiesterase type 5, and cGMP-dependent protein kinase.
Liu J; Chen Z; Ye L; Liu H; Dou D; Liu L; Yu X; Gao Y
Pflugers Arch; 2014 Oct; 466(10):1999-2008. PubMed ID: 24413911
[TBL] [Abstract][Full Text] [Related]
43. 1-(2-Ethoxyethyl)-1H-pyrazolo[4,3-d]pyrimidines as potent phosphodiesterase 5 (PDE5) inhibitors.
Tollefson MB; Acker BA; Jacobsen EJ; Hughes RO; Walker JK; Fox DN; Palmer MJ; Freeman SK; Yu Y; Bond BR
Bioorg Med Chem Lett; 2010 May; 20(10):3120-4. PubMed ID: 20443228
[TBL] [Abstract][Full Text] [Related]
44. Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD.
García-Barroso C; Ricobaraza A; Pascual-Lucas M; Unceta N; Rico AJ; Goicolea MA; Sallés J; Lanciego JL; Oyarzabal J; Franco R; Cuadrado-Tejedor M; García-Osta A
Neuropharmacology; 2013 Jan; 64():114-23. PubMed ID: 22776546
[TBL] [Abstract][Full Text] [Related]
45. Phosphodiesterase type 5 (PDE5) inhibition improves object recognition memory: indications for central and peripheral mechanisms.
Reneerkens OA; Rutten K; Akkerman S; Blokland A; Shaffer CL; Menniti FS; Steinbusch HW; Prickaerts J
Neurobiol Learn Mem; 2012 May; 97(4):370-9. PubMed ID: 22426465
[TBL] [Abstract][Full Text] [Related]
46. Brief hyperoxia increases mitochondrial oxidation and increases phosphodiesterase 5 activity in fetal pulmonary artery smooth muscle cells.
Farrow KN; Lee KJ; Perez M; Schriewer JM; Wedgwood S; Lakshminrusimha S; Smith CL; Steinhorn RH; Schumacker PT
Antioxid Redox Signal; 2012 Aug; 17(3):460-70. PubMed ID: 22229392
[TBL] [Abstract][Full Text] [Related]
47. How do phosphodiesterase-5 inhibitors affect cancer? A focus on glioblastoma multiforme.
Sanati M; Aminyavari S; Mollazadeh H; Bibak B; Mohtashami E; Afshari AR
Pharmacol Rep; 2022 Apr; 74(2):323-339. PubMed ID: 35050491
[TBL] [Abstract][Full Text] [Related]
48. PDE5 Exists in Human Neurons and is a Viable Therapeutic Target for Neurologic Disease.
Teich AF; Sakurai M; Patel M; Holman C; Saeed F; Fiorito J; Arancio O
J Alzheimers Dis; 2016; 52(1):295-302. PubMed ID: 26967220
[TBL] [Abstract][Full Text] [Related]
49. Design and synthesis of novel annulated thienopyrimidines as phosphodiesterase 5 (PDE5) inhibitors.
El-Sharkawy LY; El-Sakhawy RA; Abdel-Halim M; Lee K; Piazza GA; Ducho C; Hartmann RW; Abadi AH
Arch Pharm (Weinheim); 2018 May; 351(5):e1800018. PubMed ID: 29656464
[TBL] [Abstract][Full Text] [Related]
50. Design of novel β-carboline derivatives with pendant 5-bromothienyl and their evaluation as phosphodiesterase-5 inhibitors.
El-Gamil DS; Ahmed NS; Gary BD; Piazza GA; Engel M; Hartmann RW; Abadi AH
Arch Pharm (Weinheim); 2013 Jan; 346(1):23-33. PubMed ID: 23307609
[TBL] [Abstract][Full Text] [Related]
51. Therapeutic potentials of phosphodiesterase-5 inhibitors in cardiovascular disease.
Nguyen H; Amanullah AM
Rev Cardiovasc Med; 2014; 15(2):158-67. PubMed ID: 25051133
[TBL] [Abstract][Full Text] [Related]
52. Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection. The DEDALO project.
Isidori AM; Giannetta E; Pofi R; Venneri MA; Gianfrilli D; Campolo F; Mastroianni CM; Lenzi A; d'Ettorre G
Andrology; 2021 Jan; 9(1):33-38. PubMed ID: 32526061
[TBL] [Abstract][Full Text] [Related]
53. cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium.
Vandeput F; Krall J; Ockaili R; Salloum FN; Florio V; Corbin JD; Francis SH; Kukreja RC; Movsesian MA
J Pharmacol Exp Ther; 2009 Sep; 330(3):884-91. PubMed ID: 19546307
[TBL] [Abstract][Full Text] [Related]
54. Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one.
Hughes RO; Walker JK; Rogier DJ; Heasley SE; Blevis-Bal RM; Benson AG; Jacobsen EJ; Cubbage JW; Fobian YM; Owen DR; Freskos JN; Molyneaux JM; Brown DL; Acker BA; Maddux TM; Tollefson MB; Moon JB; Mischke BV; Rumsey JM; Zheng Y; MacInnes A; Bond BR; Yu Y
Bioorg Med Chem Lett; 2009 Sep; 19(17):5209-13. PubMed ID: 19631533
[TBL] [Abstract][Full Text] [Related]
55. Design and synthesis of pyrazolo[3,4-d]pyrimidinone derivatives: Discovery of selective phosphodiesterase-5 inhibitors.
Shaaban MA; Elshaier YAMM; Hammad AH; Farag NA; Hassan Haredy H; AbdEl-Ghany AA; Mohamed KO
Bioorg Med Chem Lett; 2020 Aug; 30(16):127337. PubMed ID: 32631538
[TBL] [Abstract][Full Text] [Related]
56. A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and β-catenin transcriptional activity.
Whitt JD; Li N; Tinsley HN; Chen X; Zhang W; Li Y; Gary BD; Keeton AB; Xi Y; Abadi AH; Grizzle WE; Piazza GA
Cancer Prev Res (Phila); 2012 Jun; 5(6):822-33. PubMed ID: 22556201
[TBL] [Abstract][Full Text] [Related]
57. Structure -activity relationships of PDE5 inhibitors.
Eros D; Szántai-Kis C; Kiss R; Kéri G; Hegymegi-Barakonyi B; Kövesdi I; Orfi L
Curr Med Chem; 2008; 15(16):1570-85. PubMed ID: 18673225
[TBL] [Abstract][Full Text] [Related]
58. Phosphodiesterase 5 as target for adipose tissue disorders.
Colombo G; Colombo MD; Schiavon Lde L; d'Acampora AJ
Nitric Oxide; 2013 Nov; 35():186-92. PubMed ID: 24177060
[TBL] [Abstract][Full Text] [Related]
59. Exploration of icariin analog structure space reveals key features driving potent inhibition of human phosphodiesterase-5.
Chau Y; Li FS; Levsh O; Weng JK
PLoS One; 2019; 14(9):e0222803. PubMed ID: 31539416
[TBL] [Abstract][Full Text] [Related]
60. Marked disparity of microRNA modulation by cGMP-selective PDE5 versus PDE9 inhibitors in heart disease.
Kokkonen-Simon KM; Saberi A; Nakamura T; Ranek MJ; Zhu G; Bedja D; Kuhn M; Halushka MK; Lee DI; Kass DA
JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
